Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $581000.0.

  • RxSight's Capital Expenditures fell 4732.55% to $581000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 4275.55%. This contributed to the annual value of $5.4 million for FY2024, which is 1300.37% up from last year.
  • According to the latest figures from Q3 2025, RxSight's Capital Expenditures is $581000.0, which was down 4732.55% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Capital Expenditures ranged from a high of $2.0 million in Q1 2024 and a low of $254000.0 during Q3 2021
  • For the 5-year period, RxSight's Capital Expenditures averaged around $909473.7, with its median value being $747000.0 (2023).
  • Per our database at Business Quant, RxSight's Capital Expenditures surged by 33950.28% in 2023 and then tumbled by 7076.77% in 2025.
  • RxSight's Capital Expenditures (Quarter) stood at $365000.0 in 2021, then dropped by 0.82% to $362000.0 in 2022, then skyrocketed by 339.5% to $1.6 million in 2023, then tumbled by 46.76% to $847000.0 in 2024, then crashed by 31.4% to $581000.0 in 2025.
  • Its Capital Expenditures stands at $581000.0 for Q3 2025, versus $1.5 million for Q2 2025 and $575000.0 for Q1 2025.